Nanogam (Human Normal Immunoglobulin)

Human Normal Immunoglobulin, the active ingredient in Nanogam, is a Immunoglobulin (human normal) presented as a solution for intravenous infusion for intravenous use. It treats primary and secondary immunodeficiency diseases by providing passive immunity. GNH USA supplies Nanogam as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide.

Nanogam is used to replace deficient antibodies in patients with primary or secondary immunodeficiency conditions. - Primary immunodeficiency diseases (e.g., common variable immunodeficiency): provides IgG antibodies to reduce infection frequency. - Secondary immunodeficiency (e.g., post‑bone marrow transplant, chemotherapy): supplies passive immunity to protect against opportunistic pathogens. - Prophylaxis of infections in antibody‑deficient patients: maintains protective antibody levels to prevent bacterial and viral infections.

Nanogam may be associated with infusion‑related reactions and immune‑mediated events.

Common Side Effects: - Headache: mild to moderate discomfort during or after infusion. - Fever or chills: transient elevation of body temperature. - Nausea: mild gastrointestinal upset. - Fatigue: temporary feeling of tiredness. - Injection site erythema: redness at the infusion site.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Thromboembolic events: blood clots such as deep vein thrombosis. - Renal impairment: acute kidney injury, especially with high infusion rates. - Hemolysis: destruction of red blood cells. - Aseptic meningitis: inflammation of meninges without infection.

When using Nanogam, clinicians should consider several safety and handling precautions. - Patient assessment: evaluate history of IgA deficiency or allergic reactions to blood products. - Infusion rate: start slowly and increase gradually to reduce adverse reactions. - Hydration status: ensure adequate fluid intake to support renal function. - Monitoring: observe vital signs during infusion and for at least 30 minutes after. - Concomitant immunosuppressants: assess increased infection risk when combined. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Nanogam can interact with certain medications and clinical conditions.

Major Interactions (Avoid): - Live vaccines: may reduce vaccine efficacy or increase risk of infection. - High‑dose aspirin or NSAIDs: increase risk of bleeding due to platelet inhibition. - Immunoglobulin‑A deficiency with anti‑IgA antibodies: risk of severe anaphylaxis.

Moderate Interactions (Monitor Closely): - Corticosteroids: may alter immune response, requiring dose adjustment. - Anticoagulants (e.g., warfarin): monitor coagulation parameters. - Diuretics: monitor renal function and fluid balance.